CHMP positive on approval for Roche’s Erivedge
This article was originally published in Scrip
Executive Summary
The EU’s CHMP has granted a positive opinion on Roche/Curis’s Erivedge (vismodegib) in basal cell carcinoma, a rare form of skin cancer, paving the way for a conditional approval in its fifth market.